Regeneron Pharmaceuticals REGN Reimbursement For Manufacturing Of Commercial Supplies — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue?
- Regeneron Pharmaceuticals (REGN) reported reimbursement for manufacturing of commercial supplies — revenue of $154.3M in Q1 2026.
- How has Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue changed year-over-year?
- Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue decreased by 6.5% year-over-year, from $165M to $154.3M.
- What is the long-term trend for Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue has grown at a 7.1% compound annual growth rate (CAGR), from $488.8M to $642.3M.
- What does reimbursement for manufacturing of commercial supplies — revenue mean?
- Revenue earned from manufacturing pharmaceutical products on behalf of collaboration partners.
- How do you interpret reimbursement for manufacturing of commercial supplies — revenue?
- An increase suggests higher production volume for partners or expanded manufacturing service agreements, while a decrease may indicate a shift in manufacturing responsibilities or lower demand for partner-marketed products.
- How does reimbursement for manufacturing of commercial supplies — revenue compare across companies?
- Comparable to contract manufacturing revenue or service-based collaboration income found in other biopharmaceutical companies with significant R&D and manufacturing partnerships.